Premium
GLP ‐1 analogue use in patients with sub‐optimally controlled type 1 diabetes or obesity improves weight and HbA 1c
Author(s) -
Curtis Louise,
Holt Helen,
Richardson Tristan,
Knott Julia,
Partridge Helen
Publication year - 2016
Publication title -
practical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.205
H-Index - 24
eISSN - 2047-2900
pISSN - 2047-2897
DOI - 10.1002/pdi.1991
Subject(s) - medicine , type 2 diabetes , diabetes mellitus , weight loss , obesity , gastroenterology , observational study , body weight , endocrinology
GLP ‐1 analogues are licensed for add‐on therapy for patients with type 2 diabetes who have sub‐optimal glycaemic control on other glucose lowering agents. Their use in patients with type 1 diabetes has been evaluated in primarily research settings. We investigated the effect of adding GLP ‐1 analogues on weight and glycaemic control in our patients with type 1 diabetes. A retrospective observational case note review of patients with type 1 diabetes between 2011 and 2014 was performed to recruit patients to this study. Inclusion criteria were established treatment with multiple daily injections or continuous subcutaneous insulin infusion and sub‐optimal glycaemic control ( HbA 1c >57 mmol/mol) or obesity ( BMI >30 kg/m 2 ). A GLP ‐1 analogue was added to pre‐existing treatment. HbA 1c and weight were measured at initiation and six monthly for up to 30 months. Thirty‐three patients were included. The addition of a GLP ‐1 analogue significantly improved mean HbA 1c from baseline at 6, 12 and 30 months (79 mmol/mol, 71 mmol/mol, 70 mmol/mol, 74 mmol/mol; all p < 0.05); and weight from baseline at 6, 12, 18, 24 and 30 months (104.9 kg, 98.0 kg, 98.5 kg, 94.7 kg, 96.2 kg, 92.0 kg; all p < 0.05). Patients with BMI <35 kg/m 2 had an improved response in both weight and HbA 1c over those with BMI ≥35 kg/m 2 . Three patients discontinued treatment due to gastrointestinal side effects. In conclusion, the addition of a GLP ‐1 analogue to existing treatment resulted in significantly improved glycaemic control and weight loss in patients with type 1 diabetes. Copyright © 2016 John Wiley & Sons.